Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-220 dose-finding and expansion study in multiple myeloma
NL-OMON59751Phase 2Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Feb 2017
- Modality
- Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of iberdomide, sponsored by Celgene Corporation. Started Feb 2017; status: active, not recruiting.
02
Drugs
iberdomide
Beyond the preview
Go deeper on NL-OMON59751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59751.